. . "\u00DAloha FLT3 mutac\u00ED v patogenezi akutn\u00ED myeloidn\u00ED leukemie" . "The role of FLT3 mutations in the pathogenesis of acute myeloid leukemia"@en . "347431" . "Receptorov\u00E1 tyrozinkin\u00E1za FLT3(FMS-like tyrosine kinase 3) je exprimov\u00E1na \u010Dasn\u00FDmi hematopoetick\u00FDmi progenitorov\u00FDmi bu\u0148kami a hraje kl\u00ED\u010Dovou roli v regualci jejich v\u00FDvoje a proliferace. Aktiva\u010Dn\u00ED mutace t\u00E9to kin\u00E1zy jsou p\u0159\u00EDtomny p\u0159ibli\u017En\u011B u 40% pacient\u016F s akutn\u00ED myeloidn\u00ED leukemi\u00ED (AML) a pat\u0159\u00ED tak k nej\u010Dast\u011Bj\u0161\u00EDm genetick\u00FDm aberac\u00EDm AML. Mutace FLT3 genu vedou ke konstitutivn\u00ED fosforylaci receptoru a k n\u00E1sledn\u00E9 aktivaci sign\u00E1ln\u00EDch drah vedouc\u00EDch k nekontrovateln\u00E9mu d\u011Blen\u00ED bun\u011Bk. Muta\u010Dn\u00ED status FLT3 genu je d\u016Fle\u017Eit\u00FDm prognostick\u00FDm ukazatelem, zejm\u00E9na p\u0159\u00EDtomnost intern\u00EDch tandemov\u00FDch duplikac\u00ED v exonech 14 a 15 znamen\u00E1 pro pacienty s norm\u00E1ln\u00EDm karyotypem zhor\u0161en\u00ED progn\u00F3zy z hlediska signifikantn\u00EDho zkr\u00E1cen\u00ED trv\u00E1n\u00ED kompletn\u00ED remise (CRD) a intervalu bez symptom\u016F nemoci (DFS). Klinick\u00FD v\u00FDznam bodov\u00FDch mutac\u00ED v tyrozikin\u00E1zov\u00E9 dom\u00E9n\u011B FLT3 genu je m\u00E9n\u011B z\u0159ejm\u00FD a je st\u00E1le p\u0159edm\u011Btem diskuse." . "1213-5763" . . "Gazdov\u00E1, Jana" . . "Transfuze a hematologie dnes" . . "6"^^ . . "\u00DAloha FLT3 mutac\u00ED v patogenezi akutn\u00ED myeloidn\u00ED leukemie"@cs . "FLT3 (FMS-like tyrosine kinase 3) is a tyrosine kinase receptor expressed by early hematopoietic progenitor cells and is essential fot its normal development and proliferation. Activating mutations of this kinase are found in approximately 40% of all AML cases and are therefore on of the most common genetic alterations observed in AML. Mutations in FLT3 gene lead to constitutive phosphorylation of the receptor and consecutive activation of downstream signalling pathways resulting in uncontrolled cell proliferation. FLT3 mutational status, especially internal tandem duplications in exons 14 and 15, appears to be a significant prognostic indicator associated with a distinctly worse clinical outcome in AML patients with normal cytogenetics in terms of shorter complete remission duration (CRD) and disease free survival (DFS). Prognostic imapct of point mutations in tyrosine kinase domain is less clear and is still under debate."@en . . "\u00DAloha FLT3 mutac\u00ED v patogenezi akutn\u00ED myeloidn\u00ED leukemie"@cs . "15" . . . "Mayer, Ji\u0159\u00ED" . . . "R\u00E1zga, Filip" . . "CZ - \u010Cesk\u00E1 republika" . . . . "14110" . "Je\u017E\u00ED\u0161kov\u00E1, Ivana" . "Dvo\u0159\u00E1kov\u00E1, Dana" . "\u00DAloha FLT3 mutac\u00ED v patogenezi akutn\u00ED myeloidn\u00ED leukemie" . "S, V" . "RIV/00216224:14110/09:00038551" . . "8"^^ . "Jur\u010Dek, Tom\u00E1\u0161" . "FLT3 receptor tyrosine kinase; cyogenetically normal AML; internal tandem duplication; prognostic marker"@en . "4" . "The role of FLT3 mutations in the pathogenesis of acute myeloid leukemia"@en . "4"^^ . "[F8163B15CF07]" . "RIV/00216224:14110/09:00038551!RIV11-MSM-14110___" . "Receptorov\u00E1 tyrozinkin\u00E1za FLT3(FMS-like tyrosine kinase 3) je exprimov\u00E1na \u010Dasn\u00FDmi hematopoetick\u00FDmi progenitorov\u00FDmi bu\u0148kami a hraje kl\u00ED\u010Dovou roli v regualci jejich v\u00FDvoje a proliferace. Aktiva\u010Dn\u00ED mutace t\u00E9to kin\u00E1zy jsou p\u0159\u00EDtomny p\u0159ibli\u017En\u011B u 40% pacient\u016F s akutn\u00ED myeloidn\u00ED leukemi\u00ED (AML) a pat\u0159\u00ED tak k nej\u010Dast\u011Bj\u0161\u00EDm genetick\u00FDm aberac\u00EDm AML. Mutace FLT3 genu vedou ke konstitutivn\u00ED fosforylaci receptoru a k n\u00E1sledn\u00E9 aktivaci sign\u00E1ln\u00EDch drah vedouc\u00EDch k nekontrovateln\u00E9mu d\u011Blen\u00ED bun\u011Bk. Muta\u010Dn\u00ED status FLT3 genu je d\u016Fle\u017Eit\u00FDm prognostick\u00FDm ukazatelem, zejm\u00E9na p\u0159\u00EDtomnost intern\u00EDch tandemov\u00FDch duplikac\u00ED v exonech 14 a 15 znamen\u00E1 pro pacienty s norm\u00E1ln\u00EDm karyotypem zhor\u0161en\u00ED progn\u00F3zy z hlediska signifikantn\u00EDho zkr\u00E1cen\u00ED trv\u00E1n\u00ED kompletn\u00ED remise (CRD) a intervalu bez symptom\u016F nemoci (DFS). Klinick\u00FD v\u00FDznam bodov\u00FDch mutac\u00ED v tyrozikin\u00E1zov\u00E9 dom\u00E9n\u011B FLT3 genu je m\u00E9n\u011B z\u0159ejm\u00FD a je st\u00E1le p\u0159edm\u011Btem diskuse."@cs . . . .